04/06/2017
Yisachar Jesse Greenberg, MD, FACC, FHRS; Suvash Shrestha, MD; On Chen, MD; Felix Yang, MD, FACC, FHRS; Robert Frankel, MD
In recent years, the use of DOACs has been increasing. All of these agents have demonstrated efficacy in the reduction of stroke and thromboembolic end points.